Top Markets
#1 MowCat MowCat +366.96%
#2 龙虾 (Lobster) 龙虾 (Lobster) +68.62%
#3 SODAX SODAX +47.33%
#4 Cortex Cortex +33.10%
#5 MANTRA MANTRA +24.62%
#6 DexNet DexNet +23.19%
#7 OpenEden OpenEden +18.34%
#8 Akedo Akedo +17.22%
#9 BNB Attestation Service BNB Attestation Service +16.69%
#10 wojak wojak +15.31%
Coin of the day
MowCat MowCat
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Biotest AG Biotest AG

Biotest AG

BIO
Rang in Aktien #7309
Biotest AG is a German biopharmaceutical company focused on the global... Biotest AG is a German biopharmaceutical company focused on the global development, manufacturing, and commercialization of biological medications. The firm organizes its activities into the Therapy, Plasma & Services, and Other segments. Its product portfolio addresses critical needs in hematology, clinical immunology, and intensive care medicine. Among its offerings are treatments for hemophilia A (such as Haemoctin and Vihuma) and hemophilia B (like Haemonine), covering both acute care and prevention. Biotest also provides therapies for various viral infections, including cytomegalovirus (Cytotect CP), hepatitis B (Fovepta, Hepatect, Zutectra), and varicella zoster (Varitect). Additionally, its products, such as Intratect and IgG Next Generation, are utilized for primary and secondary immune deficiencies, autoimmune disorders, and certain neurological conditions. The company further supplies solutions to manage circulating blood volume (Albiomin, Biseko), address clotting factor deficiencies (Cofact, Fibrinogen), and combat serious infections like community-acquired pneumonia and COVID-19 (Trimodulin), as well as general bacterial infections (Pentaglobin). Established in 1946 as Biotest Serum-Institut GmbH, the company adopted its current name, Biotest Aktiengesellschaft, in 1986. Headquartered in Dreieich, Germany, Biotest Aktiengesellschaft has been operating as a subsidiary of Grifols, S.A. since January 21, 2022.
Aktienkurs
$47.45
Zuletzt synchronisiert: 2026-05-13
Marktkapitalisierung
$1.63B
Veränderung (1 Tag)
2.04%
Veränderung (1 Jahr)
3.15%
Land
DE
Handel Biotest AG (BIO)

Kategorie

Healthcare
Gewinn für Biotest AG (BIO)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Biotest AG betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Biotest AG von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH